Hanmi Pharmaceutical showed improved performance in the first quarter. Thanks to the high growth of new combination drugs such as Rosuzet and Amosartan family, both sales and operating profit recorded the highest level in eight years. Hanmi Pharmaceutical announced on the 26th that its operating profit in the first quarter was 60.5 billion won, up 47.9% from the same period last year. Sales were 361.7 billion won, up 12.6% from the previous year, and net profit was 49.6 billion won, up 98.1%. Both sales and operating profit are the highest since the fourth quarter of 2015. 2015 was a time when Hanmi Pharm recorded record-breaking performance by successively signing contracts for the export of super-large new drug technol